» Articles » PMID: 22929469

A Nonhuman Primate Model of the Hematopoietic Acute Radiation Syndrome Plus Medical Management

Overview
Journal Health Phys
Date 2012 Aug 30
PMID 22929469
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The development of medical countermeasures against the hematopoietic subsyndrome of the acute radiation syndrome requires well characterized and validated animal models. The model must define the radiation dose- and time-dependent relationships for mortality and major signs of morbidity to include other organ damage that may contribute to morbidity and mortality. Herein, the authors define these parameters for a nonhuman primate exposed to total body radiation and administered medical management. A blinded, randomized study (n = 48 rhesus macaques) determined the lethal dose-response relationship using bilateral 6 MV linear accelerator photon radiation to doses in the range of 7.20 to 8.90 Gy at 0.80 Gy min(-1). Following irradiation, animals were monitored for complete bloodcounts, body weight, temperature, diarrhea, and hydration status for 60 d. Animals were administered medical management consisting of intravenous fluids, prophylactic antibiotics, blood transfusions, anti-diarrheals, analgesics, and nutrition. The primary endpoint was survival at 60 d post-irradiation; secondary endpoints included hematopoietic-related parameters, number of transfusions, incidence of documented infection, febrile neutropenia, severity of diarrhea, mean survival time of decedents, and tissue histology. The study defined an LD30/60 of 7.06 Gy, LD50/60 of 7.52 Gy, and an LD70/60 of 7.99 Gy with a relatively steep slope of 1.13 probits per linear dose. This study establishes a rhesus macaque model of the hematopoietic acute radiation syndrome and shows the marked effect of medical management on increased survival and overall mean survival time for decedents. Furthermore, following a nuclear terrorist event, medical management may be the only treatment administered at its optimal schedule.

Citing Articles

Pathology of acute sub-lethal or near-lethal irradiation of nonhuman primates prophylaxed with the nutraceutical, gamma tocotrienol.

Singh V, Wise S, Fatanmi O, Petrus S, Carpenter A, Lugo-Roman L Sci Rep. 2024; 14(1):13315.

PMID: 38858439 PMC: 11164941. DOI: 10.1038/s41598-024-64102-8.


Product Development within the National Institutes of Health Radiation and Nuclear Countermeasures Program.

Cassatt D, DiCarlo A, Molinar-Inglis O Radiat Res. 2024; 201(5):471-478.

PMID: 38407357 PMC: 11529828. DOI: 10.1667/RADE-23-00144.1.


Immune Dysfunction from Radiation Exposure.

Hollingsworth B, Aldrich J, Case Jr C, DiCarlo A, Hoffman C, Jakubowski A Radiat Res. 2023; 200(4):396-416.

PMID: 38152282 PMC: 10751071. DOI: 10.1667/rade-22-00004.1.


The TLR2/TLR6 ligand FSL-1 mitigates radiation-induced hematopoietic injury in mice and nonhuman primates.

Brickey W, Caudell D, Macintyre A, Olson J, Dai Y, Li S Proc Natl Acad Sci U S A. 2023; 120(50):e2122178120.

PMID: 38051771 PMC: 10723152. DOI: 10.1073/pnas.2122178120.


Early to sustained impacts of lethal radiation on circulating miRNAs in a minipig model.

Chakraborty N, Holmes-Hampton G, Gautam A, Kumar R, Hritzo B, Legesse B Sci Rep. 2023; 13(1):18496.

PMID: 37898651 PMC: 10613244. DOI: 10.1038/s41598-023-45250-9.


References
1.
Villinger F, Rowe T, Parekh B, Green T, Mayne A, Grimm B . Chronic immune stimulation accelerates SIV-induced disease progression. J Med Primatol. 2002; 30(5):254-9. DOI: 10.1034/j.1600-0684.2001.d01-57.x. View

2.
Waselenko J, MacVittie T, Blakely W, Pesik N, Wiley A, Dickerson W . Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med. 2004; 140(12):1037-51. DOI: 10.7326/0003-4819-140-12-200406150-00015. View

3.
Baranov A, Selidovkin G, Butturini A, Gale R . Hematopoietic recovery after 10-Gy acute total body radiation. Blood. 1994; 83(2):596-9. View

4.
Eldred E, TROWBRIDGE W . Radiation sickness in the monkey. Radiology. 1954; 62(1):65-73. DOI: 10.1148/62.1.65. View

5.
. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist. 2002; 67(105):37988-98. View